Google Ad

Glenmark Pharma cuts worth of COVID-19 drug by 27% to Rs 75 per pill – Home Health Choices

New Delhi: Drug agency Glenmark Pharmaceuticals on Monday mentioned it has discount of its antiviral drug Favipiravir, below the model title FabiFlu, for the remedy of sufferers with delicate to average COVID-19, by 27 per cent to Rs 75 per pill. Glenmark Pharmaceuticals had launched FabiFlu final month at a worth of Rs 103 per pill.

In a regulatory submitting Glenmark introduced a worth discount of 27 per cent for FabiFlu. The new most retail worth (MRP) is Rs 75 per tab, it mentioned.

“The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country,” the submitting mentioned.

“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country,” Glenmark Pharmaceuticals Senior Vice President and Head – India enterprise Alok Malik mentioned.

Further, the corporate has commenced a publish advertising surveillance (PMS) research on FabiFlu to intently monitor the efficacy and security of the drug in 1,00zero sufferers which can be prescribed with the oral antiviral, as a part of an open label, multicenter, single arm research, the submitting added.

“We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu,” Malik added.

On June 20, Glenmark introduced that it acquired manufacturing and advertising approval from India’s drug regulator for FabiFlu, making it the primary oral Favipiravir-approved medicine in India for the remedy of delicate to average COVID-19.

Glenmark has additionally accomplished the section three medical trial with Favipiravir (FabiFlu) in delicate to average COVID-19 sufferers in India. The trial outcomes will likely be accessible shortly, the corporate mentioned.

Glenmark can be conducting one other section three medical trial to guage the efficacy of two antivirals medication Favipiravir and Umifenovir as a mix remedy in average hospitalised grownup COVID-19 sufferers in India.

Shares of Glenmark Pharma have been buying and selling 1.34 per cent decrease at Rs 421.00 apiece on BSE.

Latest Updates

Related Post